BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma.

Deletion polymorphism of BCL-2-like protein 11 (BIM) is specifically found in East Asia. To explain some epidemiological discrepancies between Asian and Western countries, we analyzed a silent single nucleotide polymorphism (SNP) in exon 5 (c465C > T) and a deletion site (2903 bp) in intron 2 in 77 patients with follicular lymphoma by the Q-invader method using PCR. In females, 5-year progression-free survivals (PFS) were 20.

[Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire survey].

We conducted a questionnaire survey to assess the state of patients with CML after discontinuation of TKI therapy. Nine of 27 patients developed musculoskeletal pain after TKI discontinuation. One had discontinued nilotinib and eight had discontinued imatinib therapy.

[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].

A 51-year-old man with chronic myeloid leukemia (CML) was treated with imatinib (IM). After 24 months of treatment, he achieved a complete molecular response (CMR), which he sustained for 3 years. However, 4 months after discontinuing IM treatment, the CML relapsed.

Synchronous diffuse large B-cell lymphoma and squamous cell lung carcinoma.

A 68-year-old woman was referred for a nodule in the right lung and hilar and mediastinal lymphadenopathy. Physical examination revealed left cervical lymphadenopathy. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) images revealed radiotracer uptake in the pulmonary nodule and multiple lymph nodes of the truncus.